Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
Authors:
Open Access
- 30 June 2022
- journal article
- research article
- Published by Elsevier in Journal of Clinical Virology Plus
- Vol. 2 (3) , 100094
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional surveyJournal of Hospital Infection, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- US authorization of first COVID vaccine marks new phase in safety monitoringNature, 2020
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- A Review of the Progress and Challenges of Developing a Vaccine for COVID-19Frontiers in Immunology, 2020
- Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional surveyVaccine, 2020
- Vaccine hesitancy: the next challenge in the fight against COVID-19European Journal of Epidemiology, 2020
- Influenza Vaccine and Healthcare WorkersArchives of Medical Research, 2011